S. Kalaivanan, S. Showbharnikhaa, T. Thenmozhi, S. Preethi, A. Ayisha Siddiqkha, A. Hema Malini, K. Rajaganapathy, R. Srinivasan
{"title":"针对 RA 中 HMBG1 的体外和体内筛选方法:全面概述","authors":"S. Kalaivanan, S. Showbharnikhaa, T. Thenmozhi, S. Preethi, A. Ayisha Siddiqkha, A. Hema Malini, K. Rajaganapathy, R. Srinivasan","doi":"10.30574/ijsra.2024.12.2.1237","DOIUrl":null,"url":null,"abstract":"Targeting High Mobility Group Box 1 (HMGB1) in rheumatoid arthritis (RA) holds promise for mitigating inflammation and joint damage. This paper comprehensively overviews In Vitro and In Vivo screening methods for HMGB1 targeting in RA. In Vitro, assays include cell-based assays, ELISA, and Western blotting to assess HMGB1 release, receptor activation, and downstream signalling pathways. In Vivo, models such as collagen-induced arthritis (CIA) in mice and adjuvant-induced arthritis (AIA) in rats mimic RA pathogenesis and enable evaluation of HMGB1 inhibitors' efficacy, safety, and pharmacokinetics. Advanced imaging technologies, including PET and MRI, allow non-invasive visualization of HMGB1 expression In Vivo. Biomarker analyses complement screening methods by correlating HMGB1 levels with disease activity and treatment response. Integration of these screening methods facilitates the development of HMGB1-targeted therapies with the potential to transform RA management. In this review we proposed certain In-vitro and In-vivo screening methods for RA.","PeriodicalId":14366,"journal":{"name":"International Journal of Science and Research Archive","volume":"10 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In-vitro and In-vivo screening methods for targeting HMBG1 in RA: A comprehensive overview\",\"authors\":\"S. Kalaivanan, S. Showbharnikhaa, T. Thenmozhi, S. Preethi, A. Ayisha Siddiqkha, A. Hema Malini, K. Rajaganapathy, R. Srinivasan\",\"doi\":\"10.30574/ijsra.2024.12.2.1237\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeting High Mobility Group Box 1 (HMGB1) in rheumatoid arthritis (RA) holds promise for mitigating inflammation and joint damage. This paper comprehensively overviews In Vitro and In Vivo screening methods for HMGB1 targeting in RA. In Vitro, assays include cell-based assays, ELISA, and Western blotting to assess HMGB1 release, receptor activation, and downstream signalling pathways. In Vivo, models such as collagen-induced arthritis (CIA) in mice and adjuvant-induced arthritis (AIA) in rats mimic RA pathogenesis and enable evaluation of HMGB1 inhibitors' efficacy, safety, and pharmacokinetics. Advanced imaging technologies, including PET and MRI, allow non-invasive visualization of HMGB1 expression In Vivo. Biomarker analyses complement screening methods by correlating HMGB1 levels with disease activity and treatment response. Integration of these screening methods facilitates the development of HMGB1-targeted therapies with the potential to transform RA management. In this review we proposed certain In-vitro and In-vivo screening methods for RA.\",\"PeriodicalId\":14366,\"journal\":{\"name\":\"International Journal of Science and Research Archive\",\"volume\":\"10 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Science and Research Archive\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30574/ijsra.2024.12.2.1237\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Science and Research Archive","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30574/ijsra.2024.12.2.1237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
靶向类风湿性关节炎(RA)中的高迁移率组框 1(HMGB1)有望减轻炎症和关节损伤。本文全面概述了针对类风湿性关节炎 HMGB1 的体外和体内筛选方法。体外检测包括细胞检测、ELISA 和 Western 印迹法,以评估 HMGB1 的释放、受体激活和下游信号通路。体内,小鼠胶原诱导性关节炎(CIA)和大鼠佐剂诱导性关节炎(AIA)等模型模拟了 RA 的发病机制,可评估 HMGB1 抑制剂的疗效、安全性和药代动力学。包括正电子发射计算机断层显像(PET)和核磁共振成像(MRI)在内的先进成像技术可以对体内 HMGB1 的表达进行无创观察。生物标志物分析可将 HMGB1 水平与疾病活动和治疗反应相关联,从而对筛选方法起到补充作用。整合这些筛查方法有助于开发 HMGB1 靶向疗法,从而有可能改变 RA 的治疗方法。在本综述中,我们提出了一些针对 RA 的体外和体内筛查方法。
In-vitro and In-vivo screening methods for targeting HMBG1 in RA: A comprehensive overview
Targeting High Mobility Group Box 1 (HMGB1) in rheumatoid arthritis (RA) holds promise for mitigating inflammation and joint damage. This paper comprehensively overviews In Vitro and In Vivo screening methods for HMGB1 targeting in RA. In Vitro, assays include cell-based assays, ELISA, and Western blotting to assess HMGB1 release, receptor activation, and downstream signalling pathways. In Vivo, models such as collagen-induced arthritis (CIA) in mice and adjuvant-induced arthritis (AIA) in rats mimic RA pathogenesis and enable evaluation of HMGB1 inhibitors' efficacy, safety, and pharmacokinetics. Advanced imaging technologies, including PET and MRI, allow non-invasive visualization of HMGB1 expression In Vivo. Biomarker analyses complement screening methods by correlating HMGB1 levels with disease activity and treatment response. Integration of these screening methods facilitates the development of HMGB1-targeted therapies with the potential to transform RA management. In this review we proposed certain In-vitro and In-vivo screening methods for RA.